Incyte signs AI deals with Genesis Molecular AI, Edison Scientific
Over a 35-year history, Incyte has grown into a $19 billion biopharma company. The Delaware-based drugmaker is now turning to AI to power through the coming decades.
Read the full article on the original site.
Read Full Article